The Australian Medical Association Limited and state AMA entities comply with the Privacy Act 1988. Please refer to the AMA Privacy Policy to understand our commitment to you and information on how we store and protect your data.



25 Sep 2019

Patients with intestinal failure associated with Short Bowel Syndrome (SBS), and those suffering spasticity in the upper limbs, will have access to greater medicinal support, thanks to new and amended listings on the Pharmaceutical Benefits Scheme (PBS) coming into effect on October 1.

Short Bowel Syndrome is a disorder that arises from an inability to absorb food nutrients and fluid across the gastrointestinal tract, and one that is often caused by surgical removal of all or part of the small intestine.

Australians experiencing SBS will be able to purchase first time listing Revestive® (Teduglutide), a medicine that improves the absorption of nutrients and fluid from the gut.

Up to 70 patients per year will benefit from the listing, with the PBS subsidy saving patients up to $284,700 per year for treatment.

In addition, the current listing of Dysport® (clostridium Botulinum Type A Toxin – Haemagglutinin C Complex) will be extended to include patients with moderate to severe spasticity of the upper limbs, following an acute event.

Dysport® temporarily relaxes overactive or contracting muscles, and resolves stiffness in the arm and/or hand.

Health Minister Greg Hunt said up to 6,600 patients per year will benefit from that listing. Without the PBS subsidy, patients might pay more than $9,700 per course of treatment.
All of these PBS listings were recommended by the independent expert Pharmaceutical Benefits Advisory Committee.

Published: 25 Sep 2019